Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time–kill assay

Clinical management of infections caused by multidrug-resistant Enterobacteriaceae

“…The best antimicrobial combinations remain unclear, particularly because some combinations might be antagonistic or increase toxicity. The role of carbapenems in the combination regimens against carbapenemase-producing Enterobacteriaceae may be relevant; furthermore, carbapenems must be considered as part of the combination not only for isolates with low MICs (4 mg/ liter) but also for isolates showing higher values [Daikos and Markogiannakis, 2011;Pournaras et al 2011;Qureshi et al 2012;Tumbarello et al 2012].…”

“…In vitro data studying the combination of colistin plus tigecycline were contradictory [Pournaras et al 2011;Albur et al 2012;Tumbarello et al 2012]. There are some clinical data to support this combination but they are still insufficient [Qureshi et al 2012;Cho et al 2012].…”

Antimicrobial Treatment and Containment Measures for an Extremely Drug-Resistant Klebsiella pneumoniae ST101 Isolate Carrying pKPN101-IT, a Novel Fully Sequenced bla KPC-2 Plasmid

“…To date, tigecycline has been successfully used in combination with colistin for the treatment of pandrug-resistant K. pneumoniae (15,23). Unfortunately, antimicrobial administration is not always a synonym of complete eradication of the resistant isolate (22,28). Interestingly, in our case, multiple-antimicrobial administration did not select strains resistant to these drugs, pointing out that, for severe infections, it may be appropriate to combine the few agents that remain active to maximize the chance of efficacy and to minimize selection of further resistance (17).…”

Retrospective analysis of fosfomycin combinational therapy for sepsis caused by carbapenem-resistant Klebsiella pneumoniae

“…However, optimal treatment for infections caused by CRKP has not yet been defined (14). The present retrospective study involved 104 unique patients with bacteremia due to CRKP with overall mortality rate of 25%, which is substantially lower than the rates reported for CRKP in previous studies (11,15,16). Alternatively, the difference may be resulted from unrecognized confounding variables.…”

“…CRKP has become a major hospital pathogen worldwide, and infections due to this organism have been associated with high mortality (9,(11)(12)(13). The increasing prevalence and the high mortality associated with the organism underscore the importance of effective antimicrobial therapy for these serious infections.…”